BN Agrochem Ltd
BNAGROCHEMBN Agrochem Ltd's earnings have outrun its stock. EPS grew +74.3% in a year against a −8.6% price move.
The sharpest disagreement: profits are rising, but only −13% of the last 2 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (5 weeks in) while the P/E sits at the 65th percentile of its own 2-year range. Underneath, the last four quarters read improving — profit −84.7% year on year, and −13% of the last 2 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
BN Agrochem Ltd trades at ₹287, in a confirmed uptrend and 5 weeks into that stage. That is +0.6% against its own 200-day average. It sits at 30% of a 52-week range of ₹235 to ₹407. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (5 weeks and counting).
Today the stock is in a confirmed uptrend — week 5 of stage 2, confirmed. At ₹287 it trades +0.6% versus its 200-day average and sits at 30% of its 52-week range (₹235–₹407).
Against the market, two honest reads. Cumulative: over the last 7.5 years the stock moved +1,178% while the NIFTY 500 moved +164% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (5 weeks and counting; last ahead the week of 2026-07-01) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
BN Agrochem Ltd trades at 79.4× P/E, mid-range by its own standards (65th percentile). Its long-run median P/E is 56.8×, measured across 1.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 79.4× is mid-range by its own standards (65th percentile), against a long-run median of 56.8× measured over 1.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +74.3% against a −8.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
BN Agrochem Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +192.0% | — | — | — |
| Profit | +70.0% | — | — | — |
| EPS | +74.3% | — | — | — |
| Share price | −8.6% | +74.9% | +95.7% | — |
4-Factor Sector Score
47.1/100 — rank 21 of 48 in Trading · 73% evidence confidence
BN Agrochem Ltd scores 47.1 out of 100 against the 48 companies it is compared with in Trading, ranking 21. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -19.2% and the one-year return is 3.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
The four contributions add to the total exactly: 24.2 + 7 + 9.4 + 6.5 = 47.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
BN Agrochem Ltd reported ₹261 Cr of revenue in the Mar 26 quarter, +22.0% year on year. That is the 2nd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹873 Cr. The last four reported quarters add to ₹873 Cr.
FY26 revenue came in at ₹873 Cr (+192.0% on the year). The latest quarter (Mar 26) printed ₹261 Cr, +22.0% year on year — the 2nd consecutive quarter of year-over-year growth.
Acceleration check: trailing-twelve-month revenue grew +191.7% over the last 4 quarters against +1,009.8%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
BN Agrochem Ltd's operating margin is 1.6% in the Mar 26 quarter, +20.5 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −44.0% to 2.5%. The current quarter sits inside that band.
The latest quarter's operating margin is 1.6%, +20.5 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −44.0%–2.5%.
Why the margin moved: operating margin went +20.5 pp year on year while gross margin went +7.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
BN Agrochem Ltd earned ₹3.0 Cr of net profit in the Mar 26 quarter, −84.7% year on year. Full-year FY26 profit was ₹34.0 Cr. That is 1.1% of the quarter's revenue. The same quarter a year earlier earned ₹19.3 Cr. 7 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹3.0 Cr, −84.7% year on year. On the full year, FY26 printed ₹34.0 Cr (+70.0%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 2 fiscal years −13% of BN Agrochem Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹24.0 Cr of operating cash against ₹34.0 Cr of profit. After ₹1.0 Cr of capital spending, ₹23.0 Cr was left as free cash.
FY26: operating cash of ₹24.0 Cr against reported profit of ₹34.0 Cr, leaving free cash of ₹23.0 Cr after ₹1.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is −13% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −13%: the cash cycle stretched 59 days between FY24 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 59 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
BN Agrochem Ltd's cash conversion cycle runs 59 days in FY26, up from 0 days in FY24. Capital spending ran ₹2.0 Cr over the last 3 years. At FY26 sales of ₹873 Cr each day of that cycle holds about ₹2.4 Cr, so roughly ₹141 Cr sits inside the business at any moment.
FY26: debtors at 59 days, inventory at 0 days — roughly 0.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 59 days, looser than FY24's 0.
In money terms: at FY26 sales of ₹873 Cr, each day of the cycle holds about ₹2.4 Cr — so the 59-day loop keeps roughly ₹141 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹2.0 Cr over the last 3 fiscal years against ₹1.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
BN Agrochem Ltd earns a ROCE of 4% in FY26. That is up from a trough of −9% in FY24. Return on invested capital clears the cost of that capital by −7.9 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 3.9% net margin on 1.66× asset turns.
FY26 ROCE is 4%, recovered from a FY24 trough of −9% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 3.9% net margin × 1.66× asset turns × 1.13× balance-sheet leverage ≈ 7.3% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 4.1% − 12.0% = a −7.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
BN Agrochem Ltd carries total debt of ₹51.0 Cr against shareholder equity of ₹467 Cr as of Mar 26, a debt-to-equity of 0.11 — effectively unlevered. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹51.0 Cr against shareholder equity of ₹467 Cr — a debt-to-equity of 0.11. The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 52.7 points of BN Agrochem Ltd over 8 quarters, the biggest move on the register. That takes promoters to 5.9% of the company. Foreign institutions moved +0.0 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −52.7 points over 8 quarters to 5.9%; Foreign institutions: +0.0 points over 8 quarters to 0.0%. Note the structure: promoters hold under 20% — this is a widely-held company where institutions, not a family, set the direction.
🚨 Why the register moved: promoters drove it (−52.7 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
BN Agrochem Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Rashi Peripherals LtdRPTECH | 67.0/100Favorable setup71% evidence | LEADER | 21.1/35 Revenue 14.9% · PAT 34.8% · OPM change -0.1 pp 83% evidence | 15.3/25 ROCE 16.8% · OPM 3% 76% evidence | 10.8/20 P/E 19.8× · PEG — 15% evidence | 19.8/20 RS sector 68.7% · RS bench 92.3% · 1Y 182.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 15.3 + 10.8 + 19.8 = 67 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Magnus Steel & Infra Ltd517320 | 66.9/100Thin evidence · provisional56% evidence | 27.1/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.6/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 46.1% · 1Y 1449.6%6 of 7 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.1 + 18.6 + 9.2 + 12 = 66.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Shankara Buildpro LtdBUILDPRO | 63.2/100Thin evidence · provisional59% evidence | TURNING | 25.3/35 Revenue 28.8% · PAT 68.4% · OPM change 0.5 pp 88% evidence | 17.3/25 ROCE 39% · OPM 3.5% 100% evidence | 10.6/20 P/E 23.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 25.3 + 17.3 + 10.6 + 10 = 63.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Mangalam Global Enterprise LtdMGEL | 63.0/100Mixed-positive evidence65% evidence | TURNING | 24.4/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 16.6/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 14.2× · PEG — 15% evidence | 10.9/20 RS sector — · RS bench 10.1% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 24.4 + 16.6 + 11.1 + 10.9 = 63 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Vision Infra Equipment Solutions LtdVIESL | 60.7/100Thin evidence · provisional51% evidence | LEADER | 18.8/35 Revenue — · PAT — · OPM change 2 pp 13% evidence | 19.0/25 ROCE 19.6% · OPM 27% 95% evidence | 10.5/20 P/E 25.1× · PEG — 15% evidence | 12.4/20 RS sector 4.4% · RS bench 20.9% · 1Y 93.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 19 + 10.5 + 12.4 = 60.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Euro Pratik Sales LtdEUROPRATIK | 60.5/100Mixed-positive evidence69% evidence | TURNING | 14.5/35 Revenue 18% · PAT 4% · OPM change 1 pp 88% evidence | 21.1/25 ROCE 38.4% · OPM 27% 100% evidence | 14.9/20 P/E 37.6× · PEG 0.62 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 10 weeks ahead 0% evidence |
| Exact sum: 14.5 + 21.1 + 14.9 + 10 = 60.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 7Sudarshan Pharma Industries Ltd543828 | 59.8/100Mixed-positive evidence78% evidence | LEADER | 18.5/35 Revenue 38.9% · PAT 53.3% · OPM change -1 pp 83% evidence | 14.3/25 ROCE 15.1% · OPM 9% 76% evidence | 9.1/20 P/E 39.1× · PEG — 50% evidence | 17.9/20 RS sector 9% · RS bench 27.5% · 1Y 45.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 14.3 + 9.1 + 17.9 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Lloyds Enterprises LtdLLOYDSENT | 55.6/100Mixed-positive evidence71% evidence | LEADER | 21.4/35 Revenue 18.2% · PAT 100% · OPM change 1 pp 83% evidence | 9.8/25 ROCE 3.7% · OPM 6% 76% evidence | 8.7/20 P/E 1106× · PEG — 15% evidence | 15.7/20 RS sector 4% · RS bench 22.5% · 1Y 10.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 9.8 + 8.7 + 15.7 = 55.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Tembo Global Industries LtdTEMBO | 55.3/100Mixed-positive evidence70% evidence | ASLEEP | 20.0/35 Revenue 48.5% · PAT 78.2% · OPM change 1 pp 83% evidence | 18.0/25 ROCE 22.8% · OPM 11% 95% evidence | 11.3/20 P/E 11.2× · PEG — 15% evidence | 6.0/20 RS sector -24.8% · RS bench -8.2% · 1Y 10.6%5 of 10 weeks ahead 70% evidence |
| Exact sum: 20 + 18 + 11.3 + 6 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Yogi Ltd511702 | 54.5/100Mixed-positive evidence61% evidence | BREAKING OUT | 24.2/35 Revenue 100% · PAT 100% · OPM change 3.6 pp 53% evidence | 11.3/25 ROCE 12.8% · OPM 4.4% 76% evidence | 10.0/20 P/E 36.4× · PEG — 15% evidence | 9.0/20 RS sector -17.5% · RS bench -2.5% · 1Y -13.7%3 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 11.3 + 10 + 9 = 54.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Nupur Recyclers LtdNRL | 53.8/100Mixed-positive evidence68% evidence | TURNING | 15.9/35 Revenue 36.4% · PAT 1.2% · OPM change 1.1 pp 83% evidence | 16.1/25 ROCE 15.1% · OPM 6.4% 95% evidence | 9.6/20 P/E 51.8× · PEG — 50% evidence | 12.2/20 RS sector — · RS bench 60.1% · 1Y —2 of 2 weeks ahead 25% evidence |
| Exact sum: 15.9 + 16.1 + 9.6 + 12.2 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Arisinfra Solutions LtdARIS | 53.5/100Thin evidence · provisional53% evidence | ASLEEP | 18.1/35 Revenue 39.1% · PAT 100% · OPM change 4.5 pp 62% evidence | 15.3/25 ROCE 15.6% · OPM 9% 95% evidence | 10.9/20 P/E 19.3× · PEG — 15% evidence | 9.2/20 RS sector — · RS bench -2.4% · 1Y -11.4%4 of 10 weeks ahead 25% evidence |
| Exact sum: 18.1 + 15.3 + 10.9 + 9.2 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 53.4/100Thin evidence · provisional54% evidence | TURNING | 20.9/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.8/25 ROCE 18.9% · OPM 6% 76% evidence | 9.0/20 P/E 233× · PEG — 15% evidence | 9.7/20 RS sector -7.3% · RS bench 8.5% · 1Y 31.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 13.8 + 9 + 9.7 = 53.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Onix Solar Energy Ltd513119 | 52.1/100Mixed-positive evidence75% evidence | ASLEEP | 22.1/35 Revenue 100% · PAT 100% · OPM change 23 pp 95% evidence | 11.3/25 ROCE 10% · OPM 30% 76% evidence | 10.2/20 P/E 32.4× · PEG — 15% evidence | 8.5/20 RS sector -8.1% · RS bench 29.6% · 1Y 32.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 11.3 + 10.2 + 8.5 = 52.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Bizotic Commercial Ltd543926 | 51.2/100Thin evidence · provisional58% evidence | ASLEEP | 19.7/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.1/25 ROCE 26.8% · OPM 8% 76% evidence | 10.4/20 P/E 29.6× · PEG — 50% evidence | 2.0/20 RS sector -38% · RS bench -27.8% · 1Y 109.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 19.1 + 10.4 + 2 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Patel Retail LtdPATELRMART | 51.2/100Thin evidence · provisional56% evidence | TURNING | 15.7/35 Revenue 27.7% · PAT 54.4% · OPM change -1.9 pp 83% evidence | 14.6/25 ROCE 15.3% · OPM 5.2% 95% evidence | 10.9/20 P/E 19.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 10 weeks ahead 0% evidence |
| Exact sum: 15.7 + 14.6 + 10.9 + 10 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Fabtech Technologies LtdFABTECH | 51.2/100Thin evidence · provisional52% evidence | ASLEEP | 17.4/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.7/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.1/20 P/E 13.7× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 17.4 + 12.7 + 11.1 + 10 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18SG Mart LtdSGMART | 50.2/100Mixed-positive evidence90% evidence | LEADER | 14.8/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 95% evidence | 9.2/25 ROCE 10.2% · OPM 4.5% 95% evidence | 8.4/20 P/E 70.7× · PEG 1.92 65% evidence | 17.8/20 RS sector 32.1% · RS bench 51.9% · 1Y 94.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 9.2 + 8.4 + 17.8 = 50.2 · Decision use: Price leads the evidence: RS versus the benchmark is 51.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Adani Enterprises LtdADANIENT | 47.8/100Mixed-negative evidence93% evidence | LEADER | 14.6/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.7/25 ROCE 5.8% · OPM 15% 100% evidence | 7.7/20 P/E 172× · PEG 1.96 65% evidence | 16.8/20 RS sector 5.5% · RS bench 23.2% · 1Y 21.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 8.7 + 7.7 + 16.8 = 47.8 · Decision use: Price leads the evidence: RS versus the benchmark is 23.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Shiv Aum Steels LtdSHIVAUM | 47.8/100Thin evidence · provisional50% evidence | 16.7/35 Revenue — · PAT — · OPM change 0.5 pp 32% evidence | 11.5/25 ROCE 8% · OPM 3.8% 95% evidence | 7.8/20 P/E 83.3× · PEG — 50% evidence | 11.8/20 RS sector — · RS bench 35.4% · 1Y — 25% evidence | |
| Exact sum: 16.7 + 11.5 + 7.8 + 11.8 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21BN Agrochem Ltdthis pageBNAGROCHEM | 47.1/100Mixed-negative evidence73% evidence | TURNING | 24.2/35 Revenue 100% · PAT 57.3% · OPM change 20.5 pp 88% evidence | 7.0/25 ROCE 4.4% · OPM 1.6% 100% evidence | 9.4/20 P/E 79.4× · PEG — 15% evidence | 6.5/20 RS sector -19.2% · RS bench -10.6% · 1Y 3.2%8 of 8 weeks ahead 70% evidence |
| Exact sum: 24.2 + 7 + 9.4 + 6.5 = 47.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -19.2% and the one-year return is 3.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 22Hardwyn India LtdHARDWYN | 46.2/100Mixed-negative evidence83% evidence | ASLEEP | 20.5/35 Revenue 8.3% · PAT 17.5% · OPM change 3.5 pp 83% evidence | 12.3/25 ROCE 4.8% · OPM 10% 95% evidence | 11.8/20 P/E 58.3× · PEG — 50% evidence | 1.6/20 RS sector -45.2% · RS bench -15.3% · 1Y -21.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 12.3 + 11.8 + 1.6 = 46.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23MMTC LtdMMTC | 45.3/100Mixed-negative evidence86% evidence | ASLEEP | 15.1/35 Revenue 0% · PAT 100% · OPM change -5633.5 pp 88% evidence | 9.7/25 ROCE 8.7% · OPM — 84% evidence | 13.8/20 P/E 94× · PEG 0.92 100% evidence | 6.7/20 RS sector -22.9% · RS bench -3.3% · 1Y -6.7%7 of 11 weeks ahead 70% evidence |
| Exact sum: 15.1 + 9.7 + 13.8 + 6.7 = 45.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24State Trading Corporation of India LtdSTCINDIA | 44.8/100Thin evidence · provisional54% evidence | TURNING | 18.6/35 Revenue — · PAT 100% · OPM change -14.6 pp 43% evidence | 7.5/25 ROCE -0.9% · OPM — 60% evidence | 12.1/20 P/E 16.2× · PEG — 50% evidence | 6.6/20 RS sector -30.7% · RS bench -1.9% · 1Y -6.2%5 of 11 weeks ahead 70% evidence |
| Exact sum: 18.6 + 7.5 + 12.1 + 6.6 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25PTC India LtdPTC | 43.3/100Mixed-negative evidence78% evidence | ASLEEP | 13.2/35 Revenue 4.6% · PAT -26.5% · OPM change -1.3 pp 83% evidence | 13.1/25 ROCE 13.4% · OPM 3.7% 76% evidence | 10.6/20 P/E 8.5× · PEG — 50% evidence | 6.4/20 RS sector -15.3% · RS bench -0.3% · 1Y -8.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 13.1 + 10.6 + 6.4 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26RRP Semiconductor LtdRRP | 42.7/100Thin evidence · provisional51% evidence | 12.2/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 62% evidence | 5.5/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.0/20 RS sector 61.8% · RS bench 6.5% · 1Y 195.8%0 of 1 week ahead 70% evidence | |
| Exact sum: 12.2 + 5.5 + 10 + 15 = 42.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Riddhi Siddhi Gluco Biols Ltd524480 | 42.3/100Mixed-negative evidence78% evidence | LEADER | 12.1/35 Revenue 74.8% · PAT 0% · OPM change -77 pp 83% evidence | 6.4/25 ROCE 2.7% · OPM -89% 76% evidence | 7.0/20 P/E 26.4× · PEG — 50% evidence | 16.8/20 RS sector 8.9% · RS bench 26.8% · 1Y 23.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 12.1 + 6.4 + 7 + 16.8 = 42.3 · Decision use: Price leads the evidence: RS versus the benchmark is 26.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 28Neueon Corporation LtdNEUEON | 41.8/100Thin evidence · provisional56% evidence | ASLEEP | 12.4/35 Revenue 100% · PAT -80% · OPM change -3110 pp 62% evidence | 3.5/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.9/20 RS sector 16.9% · RS bench 39.6% · 1Y —7 of 12 weeks ahead 70% evidence |
| Exact sum: 12.4 + 3.5 + 10 + 15.9 = 41.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Cropster Agro Ltd523105 | 41.0/100Mixed-negative evidence65% evidence | 16.1/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence | 11.8/25 ROCE 12.4% · OPM 8.7% 76% evidence | 10.1/20 P/E 32.7× · PEG — 15% evidence | 3.0/20 RS sector -73.5% · RS bench -60.9% · 1Y -70.2%0 of 4 weeks ahead 70% evidence | |
| Exact sum: 16.1 + 11.8 + 10.1 + 3 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Hexa Tradex LtdHEXATRADEX | 37.9/100Mixed-negative evidence65% evidence | ASLEEP | 16.8/35 Revenue 0.4% · PAT 65% · OPM change 13.6 pp 62% evidence | 4.2/25 ROCE -0.1% · OPM -191.7% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.9/20 RS sector -21.2% · RS bench -6.7% · 1Y -14.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 4.2 + 10 + 6.9 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Kothari Industrial Corporation LtdKOTIC | 35.1/100Thin evidence · provisional59% evidence | ASLEEP | 19.8/35 Revenue 100% · PAT -80% · OPM change -1 pp 62% evidence | 1.8/25 ROCE -28.9% · OPM -54% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -60% · RS bench -45.5% · 1Y -60.3%0 of 7 weeks ahead 70% evidence |
| Exact sum: 19.8 + 1.8 + 10 + 3.5 = 35.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Shanti Overseas (India) LtdSHANTI | 32.4/100Thin evidence · provisional56% evidence | 11.3/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.5/25 ROCE -25.2% · OPM -216.5% 71% evidence | 13.3/20 P/E 3× · PEG — 50% evidence | 3.3/20 RS sector -61.6% · RS bench -49.7% · 1Y -60.6%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.3 + 4.5 + 13.3 + 3.3 = 32.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Dhunseri Ventures LtdDVL | 30.8/100Adverse evidence69% evidence | ASLEEP | 11.8/35 Revenue -30.8% · PAT -38.9% · OPM change -4 pp 62% evidence | 6.0/25 ROCE 6.7% · OPM -85% 95% evidence | 8.5/20 P/E 5.4× · PEG — 50% evidence | 4.5/20 RS sector -45.9% · RS bench -14.2% · 1Y -33.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 11.8 + 6 + 8.5 + 4.5 = 30.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34Uniphos Enterprises LtdUNIENTER | 29.0/100Adverse evidence69% evidence | ASLEEP | 13.1/35 Revenue -71.3% · PAT 100% · OPM change -0.9 pp 62% evidence | 3.0/25 ROCE 0.8% · OPM -3.1% 95% evidence | 8.3/20 P/E 31.9× · PEG — 50% evidence | 4.6/20 RS sector -45.2% · RS bench -25.4% · 1Y -41.1%1 of 10 weeks ahead 70% evidence |
| Exact sum: 13.1 + 3 + 8.3 + 4.6 = 29 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Oswal Agro Mills LtdOSWALAGRO | 25.9/100Adverse evidence63% evidence | ASLEEP | 4.6/35 Revenue -80% · PAT -80% · OPM change -21782 pp 83% evidence | 7.5/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -51.8% · RS bench -33.3% · 1Y -54.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 4.6 + 7.5 + 10 + 3.8 = 25.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Mardia Samyoung Capillary Tubes Company LtdMSCTC | 57.2/100Thin evidence · provisional32% evidence | 20.5/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.7/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.7/20 P/E 687× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 74.6% · 1Y 236.1%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.5 + 15.7 + 8.7 + 12.3 = 57.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 37Proventus Agrocom LtdPROV | 56.9/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.5/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 13.0/25 ROCE 11.5% · OPM 1.8% 95% evidence | 13.1/20 P/E 39.6× · PEG — 50% evidence | 11.3/20 RS sector — · RS bench 25.4% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 19.5 + 13 + 13.1 + 11.3 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38SK Minerals & Additives Ltd544584 | 55.9/100Thin evidence · provisional31% evidence | 16.2/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.4/25 ROCE 26.2% · OPM 10% 76% evidence | 10.3/20 P/E 30.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.2 + 19.4 + 10.3 + 10 = 55.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 39Monika Alcobev LtdMONIKA | 54.6/100Thin evidence · provisional22% evidence | 16.3/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.6/25 ROCE 21% · OPM 15% 57% evidence | 10.7/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -9%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.3 + 17.6 + 10.7 + 10 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 40Pramara Promotions LtdPRAMARA | 53.1/100Thin evidence · provisional47% evidence | 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence | 14.3/25 ROCE 15.2% · OPM 15% 71% evidence | 7.3/20 P/E 51.3× · PEG — 50% evidence | 14.9/20 RS sector 7.6% · RS bench 29% · 1Y 72.6%10 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 16.6 + 14.3 + 7.3 + 14.9 = 53.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 41BMW Ventures LtdBMW | 52.4/100Thin evidence · provisional26% evidence | 17.9/35 Revenue — · PAT — · OPM change 0 pp 24% evidence | 13.3/25 ROCE 13.6% · OPM 4% 57% evidence | 11.2/20 P/E 13.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 17.9 + 13.3 + 11.2 + 10 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Manbro Industries Ltd512595 | 52.0/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.4/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.3/20 RS sector -18.9% · RS bench 37.2% · 1Y 40.1%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.4 + 10 + 10.3 = 52 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Shah Foods Ltd519031 | 50.9/100Thin evidence · provisional17% evidence | 17.3/35 Revenue — · PAT — · OPM change -10.7 pp 3% evidence | 12.3/25 ROCE — · OPM -3.3% 30% evidence | 8.9/20 P/E 293× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 143.1% · 1Y — 25% evidence | |
| Exact sum: 17.3 + 12.3 + 8.9 + 12.4 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44Le Merite Exports LtdLEMERITE | 48.2/100Thin evidence · provisional46% evidence | 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence | 9.3/25 ROCE 8.6% · OPM 2.8% 71% evidence | 9.3/20 P/E 87× · PEG — 15% evidence | 10.7/20 RS sector -10.6% · RS bench 15% · 1Y 42.1%1 of 1 week ahead to 2026-05-17 100% evidence | |
| Exact sum: 18.9 + 9.3 + 9.3 + 10.7 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Keto Motors Ltd537392 | 46.8/100Thin evidence · provisional21% evidence | 17.0/35 Revenue — · PAT -41.7% · OPM change — 12% evidence | 7.3/25 ROCE -2.2% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.5/20 RS sector — · RS bench 378.2% · 1Y — 25% evidence | |
| Exact sum: 17 + 7.3 + 10 + 12.5 = 46.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Satani Bearings Ltd505703 | 45.0/100Thin evidence · provisional37% evidence | ASLEEP | 20.1/35 Revenue — · PAT 100% · OPM change — 29% evidence | 4.9/25 ROCE 1% · OPM 1.5% 76% evidence | 8.5/20 P/E 11020× · PEG — 15% evidence | 11.5/20 RS sector — · RS bench 28.3% · 1Y 153.4%0 of 10 weeks ahead 25% evidence |
| Exact sum: 20.1 + 4.9 + 8.5 + 11.5 = 45 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47A-1 LtdA1L | 41.5/100Thin evidence · provisional50% evidence | 16.1/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 11.1/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.8/20 P/E 383× · PEG — 15% evidence | 5.5/20 RS sector -26.6% · RS bench -16% · 1Y 26.3%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.1 + 11.1 + 8.8 + 5.5 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Blue Pearl Agriventures LtdBPAGRI | 38.5/100Thin evidence · provisional50% evidence | 17.1/35 Revenue 100% · PAT -46.7% · OPM change -2.5 pp 53% evidence | 7.8/25 ROCE 2.6% · OPM 2.8% 57% evidence | 8.6/20 P/E 5705× · PEG — 15% evidence | 5.0/20 RS sector -35.6% · RS bench -25.1% · 1Y -37.5%1 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 17.1 + 7.8 + 8.6 + 5 = 38.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is BN Agrochem Ltd's share price today?
BN Agrochem Ltd trades at ₹287, −8.6% over the past year. The company is valued at ₹2,728 Cr. The stock sits at 30% of its 52-week range of ₹235–₹407, +0.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 5 weeks in. — as of 31 July 2026.
What were BN Agrochem Ltd's latest quarterly results?
BN Agrochem Ltd reported revenue of ₹261 Cr and net profit of ₹3.0 Cr for the Mar 26 quarter. Revenue rose 22.0% and profit fell 84.7% year on year. Earnings per share were ₹0.30. The operating margin was 1.6%, 20.5 pp higher than a year earlier. — as of 31 July 2026.
What is BN Agrochem Ltd's revenue?
BN Agrochem Ltd reported revenue of ₹261 Cr in the Mar 26 quarter, +22.0% year on year. For the full FY26 fiscal year, revenue was ₹873 Cr (+192.0%). — as of 31 July 2026.
What is BN Agrochem Ltd's profit?
BN Agrochem Ltd earned ₹3.0 Cr of net profit in the Mar 26 quarter, −84.7% year on year. Full-year FY26 profit was ₹34.0 Cr. The operating margin ran 1.6% in the latest quarter. — as of 31 July 2026.
What is BN Agrochem Ltd's market cap?
BN Agrochem Ltd's market capitalisation is ₹2,728 Cr at a share price of ₹287. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is BN Agrochem Ltd's P/E ratio?
BN Agrochem Ltd trades at a P/E of 79.4×, at the 65th percentile of its own 2-year range, against a long-run median of 56.8×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does BN Agrochem Ltd pay a dividend?
No — BN Agrochem Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is BN Agrochem Ltd overvalued?
On its own history, BN Agrochem Ltd looks expensive against its own history: its P/E of 79.4× sits at the 65th percentile of its 2-year range (long-run median 56.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is BN Agrochem Ltd growing?
Yes — BN Agrochem Ltd is growing: latest-quarter revenue +22.0% year on year, profit −84.7%, and the margin +20.5 pp at 1.6%. The earnings engine currently reads: improving — as of 31 July 2026.
How is BN Agrochem Ltd performing?
BN Agrochem Ltd is in a confirmed uptrend, 5 weeks in. Its latest quarter's revenue rose 22.0% and profit fell 84.7% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is BN Agrochem Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 5 of stage 2), trading +0.6% versus its 200-day average and at 30% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is BN Agrochem Ltd beating the market?
Not lately — on a trailing-13-week view BN Agrochem Ltd is currently behind the NIFTY 500 (5 weeks and counting; last ahead the week of 2026-07-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 7.5 years the stock moved +1,178% against the NIFTY 500's +164% — ahead of the index over the full window. — as of 31 July 2026.
Will BN Agrochem Ltd's share price go up?
This page publishes no price forecast for BN Agrochem Ltd. What it measures instead: the share price is ₹287, the price is in a confirmed uptrend 5 weeks in. Its P/E of 79.4× sits at the 65th percentile of its own 2-year range. — as of 31 July 2026.
Who owns BN Agrochem Ltd?
Promoters hold 5.9% of BN Agrochem Ltd, foreign institutions 0.0%, domestic institutions null% and the public 94.1% (latest quarter). The biggest move on the register over the last two years: Promoters cut 52.7 points over 8 quarters. — as of 31 July 2026.
Does BN Agrochem Ltd have too much debt?
No — BN Agrochem Ltd's debt-to-equity is 0.11, and operating profit covers the interest bill 11×. FY26 borrowings were ₹51.0 Cr against equity of ₹467 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is BN Agrochem Ltd's capex?
BN Agrochem Ltd spent ₹2.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹1.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is BN Agrochem Ltd's cash flow?
BN Agrochem Ltd generated ₹24.0 Cr of operating cash flow in FY26 and ₹23.0 Cr of free cash flow after ₹1.0 Cr of capital spending. Reported profit that year was ₹34.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is BN Agrochem Ltd's profit real cash?
Not fully — over the last 2 fiscal years, −13% of BN Agrochem Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹24.0 Cr against reported profit of ₹34.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
Where is BN Agrochem Ltd in its business cycle?
BN Agrochem Ltd's FY26 operating margin was 2.5%, against a 3-year band of −44.0%–2.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 1.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the BN Agrochem Ltd story?
The sharpest disagreement: profits are rising, but only −13% of the last 2 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is BN Agrochem Ltd a stock worth studying right now?
This is not investment advice. The machine read: BN Agrochem Ltd's earnings have outrun its stock. EPS grew +74.3% in a year against a −8.6% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.